| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 05/23/2002 | US20020061853 Caspase inhibtors and uses thereof |
| 05/23/2002 | CA2632696A1 Modified clostridial neurotoxins with altered biological persistence |
| 05/23/2002 | CA2429897A1 M. tuberculosis chaperonin 10 and uses thereof |
| 05/23/2002 | CA2429894A1 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | CA2429195A1 Immunoglobulin superfamily proteins |
| 05/23/2002 | CA2428709A1 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 05/23/2002 | CA2428527A1 (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors |
| 05/23/2002 | CA2428136A1 Modified clostridial neurotoxins with altered biological persistence |
| 05/22/2002 | EP1206935A1 Th2 differentiation inhibitors |
| 05/22/2002 | EP1206934A1 Blockade of sodium channels by phenol derivatives |
| 05/22/2002 | EP1206562A2 Genetically engineered cell lines, and their uses, in particular for neurotoxicity testing |
| 05/22/2002 | EP1206554A1 Activatable recombinant neurotoxins |
| 05/22/2002 | EP1206553A2 Isomerase proteins |
| 05/22/2002 | EP1206491A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 05/22/2002 | EP1206472A1 Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent |
| 05/22/2002 | EP1206467A1 N-heterocyclic derivatives as nos inhibitors |
| 05/22/2002 | EP1206233A2 Serine proteases |
| 05/22/2002 | CN1349800A Ointment for treating traumatic injury, setting fracture and eliminating swelling |
| 05/21/2002 | US6391920 Administering hormone inhibitor; stimulant of testosterone |
| 05/21/2002 | US6391908 Oxime amide indole type sPLA2 inhibitors |
| 05/16/2002 | WO2002038561A1 Indolylmaleimide derivatives as protein kinase c inhibitors |
| 05/16/2002 | WO2001087308B1 Treatment of fibromyalgia and chronic fatigue syndrome |
| 05/16/2002 | WO2001083547A3 Anti-inflammatory compounds and uses thereof |
| 05/16/2002 | WO2001070663A3 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 05/16/2002 | WO2001040521A3 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 05/16/2002 | US20020058809 For therapy of autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, multiple sclerosis, Guillain-Barre syndrome, psoriasis |
| 05/16/2002 | US20020058700 Ion channel modulating agents |
| 05/16/2002 | US20020058681 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 05/16/2002 | US20020058630 Urea heterocycliccarbonyl-substituted aspartic or glutamic acid derivatives |
| 05/16/2002 | US20020058073 Compositions and methods for treating neck and shoulder discomfort |
| 05/16/2002 | US20020058029 Anti-CD40L, anti-B7.1 (CD80), anti-B7.2(CD86), CD40 antibody or anti-CD4 antibody; both may be administered separately or in combination, and in any order. |
| 05/15/2002 | EP1205489A1 Polypeptide and nucleic acids encoding the same |
| 05/15/2002 | EP1205478A1 p38MAP KINASE INHIBITORS |
| 05/15/2002 | EP1205191A1 Targeted modification of intracellular compounds |
| 05/15/2002 | EP1205186A1 Compositions for promoting passive elongation of vesical smooth muscle |
| 05/15/2002 | EP1204674A2 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 05/15/2002 | EP1204657A1 Piperidine and pyrrolidine derivatives displaying neuronal activity |
| 05/15/2002 | EP1204652A1 Novel succinate derivative compounds useful as cysteine protease inhibitors |
| 05/15/2002 | EP1204429A2 Sustained release formulation of a peptide |
| 05/15/2002 | CN1349523A Novel lipoic acid derivatives, their prepn., and pharmaceutical compositions containing them |
| 05/15/2002 | CN1084618C Use of serotonin antagonists (5HT3) for treatment disease |
| 05/14/2002 | CA2105071C Use of nicotinic analogs for treatment of degenerative diseases of the nervous system |
| 05/10/2002 | WO2002036741A2 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 05/10/2002 | WO2002036605A2 Estrone-derivatives having cytoprotective activity |
| 05/10/2002 | WO2002036599A1 Thieno[2,3-c]isoquinolines for use as inhibitors of parp |
| 05/10/2002 | WO2002036543A1 Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride |
| 05/10/2002 | WO2002036151A2 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies |
| 05/10/2002 | WO2002036118A2 Heterocyclic derivatives useful as pharmaceutical agents |
| 05/10/2002 | WO2002036107A2 Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing coumpounds |
| 05/10/2002 | WO2001093890B1 Botulinum toxin implant |
| 05/10/2002 | WO2001093827B1 Neurotoxin implant |
| 05/10/2002 | WO2001068697A3 Methods and compositions for immunoregulation |
| 05/10/2002 | WO2001066742A3 G-protein coupled receptors |
| 05/10/2002 | WO2001038326A3 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 05/10/2002 | WO2001034157A9 Protease inhibitors |
| 05/10/2002 | WO2000058339A3 50 human secreted proteins |
| 05/10/2002 | WO2000050639A3 Gene sequence variations with utility in determining the treatment of disease |
| 05/10/2002 | CA2431641A1 Treatment of motor fluctuations |
| 05/10/2002 | CA2427533A1 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies |
| 05/10/2002 | CA2427518A1 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 05/10/2002 | CA2395324A1 Expression potentiator for protein synthesis regulatory gene |
| 05/09/2002 | WO2002036153A1 Expression potentiator for protein synthesis regulatory gene |
| 05/09/2002 | US20020055526 Modulators of SKCa, IKCa and BKCa channels. |
| 05/09/2002 | US20020055481 DNA that represents the splicing enhancer sequence (SES) in exon 45 of human dystrophin gene, and serves as a template in preparation of the antisense oligonucleotide, which is used to induce exon 45 skipping |
| 05/09/2002 | US20020055467 Truncated neublastin, of the glial cell-derived nerve growth factor (GDNF) subfamily; when dimerized, binds to a RET (a receptor tyrosine kinase) polypeptide |
| 05/09/2002 | US20020055142 Major intrinsic protein (MIP)-like polynucleotides, polypeptides, and antibodies |
| 05/08/2002 | EP1203958A2 High-throughput screening method |
| 05/08/2002 | EP1203024A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 05/08/2002 | EP1203005A2 25 human secreted proteins |
| 05/08/2002 | EP1202994A1 New compounds |
| 05/08/2002 | EP1202990A2 Neurotrophic pyrrolidines and piperidines, and related compositions containing them |
| 05/08/2002 | EP1202976A1 Pyrazinones, compositions containing such compounds |
| 05/08/2002 | EP1202970A1 Cyclic amine derivatives for the treatment of neurological diseases |
| 05/08/2002 | EP1202722A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 05/08/2002 | EP1202721A1 Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| 05/08/2002 | EP1202720A1 Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy |
| 05/08/2002 | CN1348460A Acetal Benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 05/08/2002 | CN1348454A Tetracyclic azepinoindole compounds as 5-HT receptor ligands |
| 05/08/2002 | CN1348372A 药物用途 Drug use |
| 05/08/2002 | CN1348370A Cyclic protein tyrosine kinase inhibitors |
| 05/07/2002 | US6384077 Highly purified EPA for treatment of schizophrenia and related disorders |
| 05/07/2002 | US6383526 Extraction in alcohol of valerenic acid while minimizing valepotriates and valepotriate degradation products; used as sedative, muscle relaxant, or anxiolytic agent |
| 05/07/2002 | US6383509 Continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years; neurotoxin, especially botulinum toxin or clostridial neurotoxin, within a polymeric matrix |
| 05/02/2002 | WO2002035240A2 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors |
| 05/02/2002 | WO2002035235A2 Net as regulator of angiogenic expression |
| 05/02/2002 | WO2002034783A2 Transmembrane proteins |
| 05/02/2002 | WO2002034753A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034718A1 Amide derivatives as nmda receptor antagonists |
| 05/02/2002 | WO2002034716A2 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | WO2002034264A1 Remedies for amyotrophic lateral sclerosis (als) |
| 05/02/2002 | WO2002034243A2 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | WO2002034242A2 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | WO2002034199A2 Medicine intended for treatment of multiple sclerosis |
| 05/02/2002 | WO2001089450A3 Treating musculoskeletal disorders using lp85 and analogs thereof |
| 05/02/2002 | WO2001077137A9 Albumin fusion proteins |
| 05/02/2002 | WO2001062923A3 Transporters and ion channels |
| 05/02/2002 | WO2001061008A3 Polypeptides and nucleic acids encoding same |
| 05/02/2002 | WO2001055210A3 Human cyr61 |
| 05/02/2002 | WO2001046394A3 Mammalian protein phosphatases |
| 05/02/2002 | WO2001034767A3 22 human secreted proteins |